YODI LAB
ActiveSummary
The computed 12-month bankruptcy probability of YODI LAB is 2.0% (moderate). The 2025 annual accounts show equity of €8,565 and a net result of -€3,252. Its solvency ranks better than 95% of 11693 sector peers (fiscal year 2025). The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
This company filed its last 2 accounts on average 54 days before the deadline; the sector median for financial year 2024 is 3 days before the deadline, and 39% of the sector filed late.
Checked, nothing found (2)
History
Go further with this company
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2025, micro schema
Untick a line to hide it. Point at a year (or use the arrow keys on the chart) for the exact figures; the table below gives them all.Sector: the middle half (P25 to P75) of NACE 46, Wholesale trade, each year against the same schema; no band under 30 filings. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA).
Peer companies
Historical observationOf the 3,225 companies that looked in July 2024 the way this one looks now, 3.3% went bankrupt within 24 months and 88% are still going.
- Micro
- 2 to 5 years old
- solvency 30% or more
- a loss of 10% of the balance sheet or more
A further 0.2% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a bankruptcy probability of 2.0% over twelve months; the group does not contradict it.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,341 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 1.0% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 3,225 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €185 | €175 | ▼ 5.2% |
| Other operating charges640/8 | €496 | €915 | ▲ 84.3% |
| Gross operating margin9900 | -€3,440 | -€1,945 | ▲ 43.5% |
| Operating profit (loss)9901 | -€4,121 | -€3,034 | ▲ 26.4% |
| Financial income75/76B | - | €52 | - |
| Recurring financial income75 | - | €52 | - |
| Financial charges65/66B | €62 | €269 | ▲ 335% |
| Recurring financial charges65 | €62 | €269 | ▲ 335% |
| Profit (loss) for the period before taxes9903 | -€4,183 | -€3,252 | ▲ 22.3% |
| Profit (loss) for the period9904 | -€4,183 | -€3,252 | ▲ 22.3% |
| Profit (loss) for the period to be appropriated9905 | -€4,183 | -€3,252 | ▲ 22.3% |
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Assets | |||
| Total assets20/58 | €12,590 | €8,948 | ▼ 28.9% |
| Formation expenses20 | €691 | €516 | ▼ 25.3% |
| Current assets29/58 | €11,898 | €8,432 | ▼ 29.1% |
| Amounts receivable within one year40/41 | €720 | €51 | ▼ 93.0% |
| Other amounts receivable41 | €720 | €51 | ▼ 93.0% |
| Cash at bank and in hand54/58 | €11,178 | €8,382 | ▼ 25.0% |
| Equity and liabilities | |||
| Total equity and liabilities10/49 | €12,590 | €8,948 | ▼ 28.9% |
| Equity10/15 | €11,817 | €8,565 | ▼ 27.5% |
| Contributions10/11 | €16,000 | €16,000 | = |
| Profit (loss) carried forward14 | -€4,183 | -€7,435 | ▼ 77.7% |
| Amounts payable17/49 | €772 | €383 | ▼ 50.4% |
| Amounts payable within one year42/48 | €772 | €383 | ▼ 50.4% |
| Trade debts44 | €748 | €383 | ▼ 48.8% |
| Suppliers440/4 | €748 | €383 | ▼ 48.8% |
| Other amounts payable47/48 | €24 | - | - |
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Profit (loss) for the period9904 | -€4,183 | -€3,252 | ▲ 22.3% |
| + Depreciation and write-downs630 | €185 | €175 | ▼ 5.2% |
| Operating cash flow (approximation) | -€3,998 | -€3,077 | ▲ 23.0% |
| Change in cash | - | -€2,796 | - |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
06-05
State Gazette act
Resignations: Claeys Pharmaceuticals & Care CommV, Roverland CommV and Ginisis BVAppointment: Befas BV (non-statutory director) · Power of attorney · Registered-office move9 facts ▸
- General meeting, 04-02-2026
- Director resignation, Claeys Pharmaceuticals & Care CommV (director)
- Director resignation, Roverland CommV (director)
- Director resignation, Ginisis BV (director)
- Power of attorney, A&Co Accountants
- General meeting, 01-03-2026
- Director appointment, Befas BV (non-statutory director)
- Power of attorney, A&Co Accountants
- Registered-office move, 3570 Alken, Medegatstraat 66
About the unread acts
Of the 2 Belgian State Gazette acts we know for this company, 1 has been read. The other one has not been read yet: what they contain is neither established nor disproved here.
Directors · office · real estate
Board 1
Permanent representatives 1
Not every act has been read: a resignation may be missing here
1 establishment unit
1 parcel
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 73302D0992/00F000 | Flanders | 1,985 m² | 1 · 244 m² | 1.9 m |
Linked by address, not proof of ownership
Mandate history
- Board
- began earlier
| Name | Functions and periods |
|---|---|
| BEFAS |
|
| Claeys Pharmaceuticals & Care CommV |
|
| Ginisis BV |
|
| Roverland CommV |
|
Structure & network
Connections & network
7 connected companiesShow 3 more companies with a shared director
Similar companies · same sector, comparable size
Company details
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 1 October 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.